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ABSTRACT

CHARACTERIZATION OF THE HEPATITIS C VIRUS GENOME INTERACTIONS
WITH THE microRNA miR-122: POTENTIAL NEW THERAPEUTIC TARGETS FOR
PEPTIDE NUCLEIC ACID BASED STRATEGIES

By
Valerie M. Schrott
May 2012

Thesis supervised by Dr. Mihaela-Rita Mihailescu
Hepatitis C virus (HCV), a positive-sense RNA virus that chronically infects
between 2.7 and 3.9 million Americans, is highly mutational, making the HCV infection
difficult to treat. Thus, it is of high interest to search for highly conserved therapeutic
targets within the HCV genome. Two such sequences are located within the 5’
untranslated region (UTR) of HCV, being complementary for the microRNA miR-122, a
liver microRNA essential for the production of the infectious virus. The use of peptide
nucleic acids (PNAs) as therapeutic agents has become a promising area of study in
recent years. In this study, we characterized the interactions between miR-122 and the
HCV 5’UTR and designed PNAs to disrupt these interactions and thus, inhibit RNA
replication and translation. Our results show that the PNAs effectively disrupt the
interactions involving miR-122 and the 5’UTR, thereby increasing the possibility of a
new therapeutic option against HCV.
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Chapter 1: Introduction
1.1 HCV: history and background
In 1975, Feinstone et al. studied transfusion-associated hepatitis and determined
that a portion of the cases were caused by an unidentified infectious agent[1] that would
be known as Non-A, Non-B Hepatitis (NANBH). 14 years later, this infectious agent
was identified as Hepatitis C Virus (HCV), a single stranded RNA virus of between
5,000-10,000 nucleotides (nts) with one continuous open reading frame (ORF)[2].
HCV is a member of the Flaviviridae family, which contains three genera:
Flavivirus, Pestivirus, and Hepacivirus. The three genera, all positive stranded RNA
viruses, contain similar virion morphologies, genome organization, and replication
strategies, but have diverse biological properties. HCV is a member of the Hepacivirus
genus. There are at least six major genotypes, each with their own subtypes, the most
common of which is genotype 1.
The beginning days of HCV research were slow due to a lack of efficient cell
cultures and small animal models. The original research to define physical properties and
pathogenesis of the virus was performed on clinical samples. The early cell lines that
supported HCV replication were not robust enough for major studies, but in 1997 Yanagi
et al.

constructed a stable full-length cDNA clone of a strain of genotype 1a[2].

Injection of these RNA transcripts into the liver of a chimpanzee resulted in viral
replication, but there was still a lack of a reliable in vitro propagation system.
Subgenomic replicons of genotype 1b were created followed by genotypes 1a and 2a, all
of which were applicable in a number of cell culture systems[3, 4].
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1.2 Hepatitis C Virus
HCV can be classified into six genotypes based on phylogenetic analysis[5].
Genotype 1, the most common genotype, is the most difficult to treat. According to the
Center for Disease Control, in 2009 there were an estimated 16,000 new HCV infections
and between 2.7-3.9 million Americans chronically infected with the virus[6]. Chronic
liver disease results in approximately 12,000 deaths annually in the United States[6].
7,427 HCV related deaths were reported in 2004[7], proving that HCV is a serious
problem affecting millions of people.
HCV is a blood borne infection, most commonly transmitted through intravenous
drug usage. Approximately 15% of individuals infected with HCV will have acute
symptoms, and the virus will clear up on its own. Unfortunately the other 85% of
infections lead to chronic HCV, which infects the liver and can lead to chronic liver
disease, liver cirrhosis, and liver cancer.

The most common form of treatment is

currently combination therapy with pegylated interferon and ribavirin. This treatment is
only effective in about 50% of individuals infected with genotype 1, the most common
form of the virus[6].
1.3 Genomic Organization
HCV has a 9.6 kb genome encoding for an open reading frame (ORF) flanked by
highly structured 5’ and 3’ untranslated regions (UTRs).

The ORF encodes an

approximately 3,000 amino acid polyprotein that is proteolytically cleaved into 10 viral
proteins: 3 structural and 7 nonstructural proteins. The structural proteins are the core
protein and the two envelope glycoproteins, and the nonstructural proteins are NS2, NS3,
NS4A, NS4B, NS5A, and NS5B (Figure 1).
2

Figure 1

HCV genome organization including structural and non-strucutral proteins. The 5’UTR consists
of four highly structured domains (I-IV) and contains the internal ribosome entry site (IRES).
The 3’UTR consists of 40 nt variable region, a poly (U/UC) tract and a highly conserved 98 nt
region named X RNA. The structural proteins are labeled in pink, and the nonstructural proteins
are labeled in yellow (adapted from[8]).

Figure 2

HCV viral particle
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The HCV viral particle is 30-80 nm across and is composed of a lipid envelope
with two envelope glycoproteins, E1 and E2, surrounding the viral core nucleocapsid that
encloses the genomic RNA (Figure 2).
The core protein is thought to multimerize and bind the HCV genome to form the
viral nucleocapsid[9]. The envelope glycoproteins most likely mediate HCV attachment
to hepatocytes and virion and membrane fusion with the cellular membrane. There is
also a p7 protein that is essential for infectivity in vivo, but its association with the virion
is unknown. Each nonstructural protein has a different role in the viral life cycle: NS2 is
a cysteine protease, and NS3 and NS4A assembled to form an active serine protease.
NS4A facilitates the recognition of RNA substrates by NS3, whose C-terminal end is an
RNA helicase and N-terminal domain is a serine protease.

NS4B is an integral

membrane protein involved in the formation of a membranous web required for RNA
replication. NS5A has an important, but unclear role in RNA replication, whereas NS5B
is the RNA-dependent-RNA polymerase (RdRP) needed for RNA replication ([9-12] and
references therein).
The HCV 5’UTR is 341 nts long, folding into four major stem-loop motifs (I-IV)
and a pseudoknot.

Domains II-IV encode the internal ribosome entry site (IRES)

required for cap independent translation of the ORF (Figure 1). The first 125 nucleotides
are required for RNA replication[13]. The 40S ribosome binds to the IRES to create an
IRES-40S complex that, with the help of eukaryotic initiation factor (eIF)-3 and MettRNA-eIF2-GTP, produces a 48S rRNA complex at the translation initiation codon
(AUG) to begin translation of the ORF[12]. Subdomain IIId of the IRES is important for
IRES function in translation[14] and contains a hairpin loop that is 100% conserved
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among all HCV genotypes. It also plays an important role in the IRES interaction with
the 40S ribosome[15].
The HCV 3’ UTR contains a 40 nt variable region, a poly (U/UC) tract and a
highly conserved 98 nt region named X RNA, which is essential for RNA replication [1618]. There are two proposed conformations within the 98-nt sequence, both containing
an extreme 3’ terminal SL1 stem-loop (Figure 3). However, two conformations are
proposed to exist for the first 55 nucleotides of X RNA (X55 RNA), which are 100%
conserved among all HCV genotypes. The first predicted conformation of the X55 RNA
includes two stem-loops (SL2 and SL3), whereas the second includes an extended single
stem-loop containing internal bulges[16, 18].

As indicated by its high level of

conservation, this sequence is essential to the virus life cycle[19]. Within the X55 RNA,
there is a 16-nt palindromic sequence named the “dimer linkage sequence” (DLS) that is
responsible for the homo dimerization of HCV RNA[20].

Work in our laboratory

showed that the HCV genome dimerization involves the formation of a kissing complex
intermediate which is converted to the more stable extended duplex by the core
protein[19]. It has also been suggested that the X55 RNA takes part in long-range kissing
interactions with a conserved stem-loop located in the NS5B coding region of HCV[17,
21], interactions absolutely essential for HCV replication.

5

Figure 3

Alternate conformations of the HCV 98 nt XRNA region.
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1.4 HCV Life cycle
HCV enters the hepatic cell as a single-stranded positive strand RNA, which is
translated using the translation machinery of the host cell and the IRES into a long
polyprotein which is cleaved into structural and nonstructural proteins by a combination
of host and HCV proteases. One of the nonstructural proteins, NS4B is involved in the
formation of a membranous web in which the HCV RNA replication occurs[22]. During
RNA replication, a minus strand RNA is produced which is used as a template to produce
many more plus strands in an estimated ratio of 10 plus strands for every minus
strand[23].

The HCV plus strand has three functions: a template for translation, a

template for RNA replication, and to become the new genomic RNA that will be
packaged into new virions. These numerous plus strands will be packaged and released
from the original cell to infect new cells (Figure 4).
There is greater than 1,000-fold excess of HCV proteins over the RNA, showing
that translation occurs at a much higher rate than replication[24]. The core protein has
been shown to be involved in translation initiation as well as dimerization of the HCV
genome[19, 25]. Translation of the non-structural proteins involved in replication must
occur at sufficient levels before the HCV genome is recruited into a replicase, or
replication complex, made of the membranous web in which all HCV proteins
accumulate on[22].

7

Figure 4

HCV viral life cycle. The viral particle is shown in pink and enters the cell before releasing the
genomic RNA which undergoes translation and replication (in the membranous web). The viral
particles are packaged and subsequently released from the cell.

8

1.5 Rationale – miR-122 and the HCV 5’UTR
It has been shown that the microRNA miR-122, which is highly abundant in the
human liver, regulates the accumulation of HCV and is essential for the production of
infectious virus[26]. microRNAs (miRNA) are small RNAs that are typically 21 to 24
nts in length whose normal cellular function is to regulate the translation of specific
messenger RNA targets, by mechanisms that are not fully understood. The miRNA
binding sites are typically found in the 3’ untranslated region of their messenger RNA
(mRNA) target sites, being recognized by nts 2-7 within miRNAs, representing the “seed
sequence”. Currently, over 400 miRNAs, regulating 60% of protein-encoding genes,
have been identified in humans[27, 28]. These miRNAs are encoded as genomic DNA
that is transcribed by RNA polymerase II into a primary miRNA (pri-miRNA), which is
cleaved by the type III ribonuclease Drosha into a short, double-stranded hairpin structure
of precursor miRNA (pre-miRNA) (Figure 5). Exportin 5 (exp 5) then exports the premiRNA from the nucleus into the cytoplasm where the RNase Dicer interacts with the 3’
end of the hairpin, cleaving loop to create a miRNA duplex of which one strand, with the
help of the Argonaut (Ago) protein, is degraded and the second strand goes on to become
a mature miRNA. The mature miRNA, along with Dicer, and Ago, is incorporated into
the RNA-induced silencing complex (RISC) by interacting directly with the Ago protein.
The Ago protein contains a PAZ domain, which binds the single-stranded RNA or the 3’
overhang of double stranded RNA, and a PIWI domain, which is a conserved binding site
for the 5’ end of the miRNA. The mature miRNA directs the RISC complex to the target
mRNA sequence to either degrade the mRNA transcript or inhibit translation (Figure 5).

9

Figure 5

microRNA biogensis in animals. Pol, Polymerase; DGCR8, DiGeorge Critical syndrome Region
8; Exp, Exportin; TRBP, Tat-Responsive element Binding Protein; Ago, Argonaute (adapted
from [29]).
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The miRNA miR-122 that positively regulates the accumulation of HCV was
found in high abundance in human liver cells and in Huh7 cells, a hepatoma cultured cell
line[30]. This miRNA, which is normally involved in regulation of lipid and cholesterol
biosynthesis in the liver, accounts for more than 70% of the miRNAs present in
hepatocyte[31]. Initially, two seed sequence targets of miR-122 miRNA were predicted
and subsequently found to be conserved across all six HCV genotypes.

The first

sequence was found within the 3’UTR, whereas the second was located within the
5’UTR. In contrast to most miRNAs, the seed sequence within the 3’UTR had no effect
on the level of HCV RNA, however, mutations of nucleotides within the 5’UTR were
shown to decrease levels of HCV RNA, and complementary mutations within miR-122
increased viral levels to normal. A second seed sequence within the 5’UTR was found 14
nts downstream of the original seed-match, and they were determined to function
cooperatively with each other[32] (Figure 6A).
miR-122 is involved in a direct interaction with two binding sites complementary
to its seed sequence within the 5’UTR of HCV viral RNA (named S1, and S2) and was
found to play a major role in increasing the abundance of HCV through stimulating
translation as well as affecting RNA replication[32-34]. According to Jangra et a.l, S1
and S2 display equal importance in translation, but S1 is more important than S2 for
efficient RNA replication[35].
In recent years, theories have surfaced that the remaining unbound portions of the
3’ region of miRNAs can exhibit pairing with supplementary sites within the mRNA to
enhance specificity or compensate for a mismatch to the seed site. These sites are known
as 3’-supplementary sites and 3’-compensatory sites, respectively[36]. The 3’

11

A.

B.

C.

Figure 6

miR-122 interactions with the first 46 nt of the HCV 5’UTR. A) Complementary seed sequence
binding sites S1 and S2 within the 5’UTR. B) Proposed simultaneous binding of two miR-122
strands to S1 and S2. C) Proposed binding of one miR-122 to S2 with supplemental binding seen
with nucleotides 13-18. Green oval points out the G-U wobble base pair seen in our NMR
experiments.
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supplementary sites are found on nts 13-16 of the miRNA, but miRNAs containing them
have been found to be only slightly more effective than those without supplementary
pairing[37]. Nucleotides 13-16 within miR-122 genotypes are highly conserved and are
potential 3’-supplementary sites (Figure 6C).
It has been proposed that miR-122 occupies S1 and S2[32], but the mechanism by
which it does so is not well characterized. It is important to discover the role of miR-122
in viral replication, as its interactions with the 5’UTR HCV RNA have the potential to
provide new therapeutic targets for the inhibition of HCV replication and/or translation.
1.6 Rationale – PNA
Peptide nucleic acid (PNA) is a synthetic DNA/RNA mimic with a modified
backbone

containing

an

uncharged

N-(2-aminoethyl)-glycine

phosphodiester backbone of nucleic acids (Figure 7A and B).

instead

of

the

This change in the

backbone structure renders proteases and nucleases unable to degrade PNAs, making
them more stable than an RNA/DNA backbone[38]. Although they preferentially form
P-form helices[39, 40], because of their flexibility, they are able to form the DNA B-form
helix, as well as the RNA A-form helix. Three duplex structures, which are stabilized by
Watson-Crick base paring, PNA-DNA, PNA-RNA, and PNA-PNA, as well as a triplex
PNA-PNA-DNA (PNA2-DNA) complex stabilized by Hoogsteen base pairing have been
identified. [39-42]. PNA duplexes are neutral and do not result in electrostatic repulsion
between the PNA and its target and are more thermodynamically stable than a DNADNA or RNA-RNA duplex. Because of this, PNAs have a higher affinity to DNA or
RNA than the DNA or RNA does to itself.

This knowledge can be applied to use PNAs

as an inhibitor of miRNA activity by preferentially binding miRNA to PNA over mRNA.
13

Figure 7

Various backbones A) DNA ribose-phosphate backbone B) traditional PNA N-(2-aminoethyl)glycine backbone C) Chiral γ-PNA backbone D) R-miniPEG γ-PNA backbone.

14

PNAs are being developed as potential therapeutic agents. The potential medical
applications of PNAs include hybridization techniques for genetic detection, “preSouthern” blotting, array hybridization, hybridization detection by mass spectrometry,
nucleic acid biosensors, modulation of polymerase chain reaction (PCR) analysis, tools
for genome mapping, and antisense and antigene drug approaches[43]. Although the
neutrality of PNAs leads to greater stability, it also results in inefficient entry of PNAs
into eukaryotic cells as well as potential aggregation issues. Numerous cell-penetrating
peptides (CPPs) have been discovered that are capable of translocating various cargos
across the cell membrane, but their mechanism of action is not well characterized[44].
Ivanova, G.D et al. . showed that for PNAs containing Lys residues that target cytosolic
targets such as microRNAs, conjugation with a CPP is not necessary[45]. The addition
of an (S)-Me stereogenic center at the γ-backbone position of the PNA (Figure 7C)
transforms single-stranded PNA into a right-handed helix with the ability to invade mixsequence double helical B-form DNA through Watson-Crick base pairing[46]. These γPNAs have poor water solubility and aggregate easily.
The PNAs designed and used in this work were produced in the Ly laboratory at
Carnegie Mellon University, and they are modified by (R)-MiniPEG (MP) at the γ
position[47] (Figure 7D). This MP is relatively small and hydrophilic and can improve
water solubility and biocompatibility with non-biological systems as well as suppress
aggregation and nonspecific binding. By adding the MP as an R steroisomer, the PNA
formed a B-from helix with the ability to invade any sequence of B-DNA independent of
G-C content[47].
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This study had the following specific aims:
Specific Aim 1: Characterization of the Hepatitis C Virus 5’ UTR interactions with the
microRNA miR-122
Specific Aim 2: Design peptide nucleic acids with antiviral activity that aim to disrupt
the interactions between miR-122 and HCV and test their activity in vitro

1.7 Relevance
HCV is a highly mutational and persistent virus without a 100% effective
treatment. Developments in potential treatments for HCV infection must focus on highly
conserved regions within the RNA genome due to their extreme importance in viral
replication and translation. The two seed sequences for miR-122 within the 5’UTR of
HCV are 100% conserved and are highly desirable for the focus of potential therapeutic
strategies. The current study aims to first understand the interactions between miR-122
and its seed sequences to further understand the role those interactions play in the viral
life before studying how the addition of PNA can be applied as a potential therapeutic
target for the virus. Thus, the significance of this work is that it will contribute to our
understanding of the miR-122 interaction with the 100% conserved seed sequences
within the 5’UTR of HCV and help in the development of peptide nucleic acids with
therapeutic function.
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Chapter 2: Materials and Methods
2.1 RNA samples
The RNA samples used in this study (miR-122 (ss), 5’UTR (+), 3’UTR (-)),
whose sequences are listed in table 1, were synthesized by Dharmacon RNAi
Technologies, a division of ThermoScientific. Unless otherwise stated, RNA samples
were snap-coooled by boiling the sample for 3 minutes, followed by immediate
placement into a dry ice/ethanol mixture for 7 minutes before being cooled at room
temperature for 15 minutes. This snap-cooling treatment induced the RNA into the stemloop secondary structure seen for the majority of the RNA used.
Table 1: List of RNA sequences used in this study

Sample Name
miR-122 (ss)

Sequence
5’ – UGAGUGUGACAAUGGUGUUUGU – 3’

5’UTR (+)

5’ – CAGGGGAGUGAUUCAUGGCGGAGUGUCGCCCCUAUUA
GGGGCAGGU – 3’
5’ – ACCUGCCCCUAAUAGGGGCGACACUCCGCCAUGAAUC
ACUCCCCUG – 3’

3’UTR (-)

2.2 Electrophoretic Mobility Gel Shift Assay (EMSA)
10-20% native polyacrylamide gels were used for electrophoretic mobility shift
assays of the various RNA/RNA or RNA/PNA interactions. 5’UTR-miR-122 gels were
run in the presence of TBE (Tris Borate EDTA) buffer at 4°C at 40 to100 V for 4 to16
hours. Upon addition of the PNAs, the respective RNA samples were incubated for 30
min to 4 hours at 37°C (physiological temperature) before being run in the presence of
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TB (Tris Borate) salt buffer at 37 °C at 60 V for 2 to 4 hours. The buffer used for PNA
samples contained 10 mM cacodylic acid pH 6.5, 10 mM NaCl, and 150 mM KCl.
Visualization of the gels was done using an AlphaImager HP (AlphaInnotech,
Inc). UV shadowing at 254 nm was used for RNA concentrations above 5 μM, staining
with ethidium bromide was used for concentrations between 1 μM and 5 μM, and
staining with SYBr Gold was used for concentrations below 1 μM followed by ultra
violet (UV) trans-illumination.

2.3 1H NMR spectroscopy
Experiments were performed on a Bruker AVANCE 500 MHz Nuclear Magnetic
Resonance Spectrometer (NMR) at 25°C in a 90% H2O/10% D2O buffer in a Shigemi
Symmetrical NMR tube. 5’UTR (+) RNA had a concentration of 169.2 μM. Singlestranded miR-122 was also analyzed at a concentration of 238 μM. NMR was also
performed on 5’UTR (+) incubated with miR-122 in both a 1:1 and 1:2 ratio, using 169.2
μM as the concentration of 5’UTR (+). All data were analyzed using the Bruker software
Topspin 2.1.

2.4 Cell growth – RNA samples
The plasmid pMCGL-T7 mutant was provided by Dr. Stanley Lemon’s laboratory
at the University of North Carolina, Chapel Hill. This plasmid contains a T7 promoter
site, XbaI restriction site, and the gene for ampicillin resistance. The Lemon laboratory
inserted the HCV 5’UTR, luciferase reporter gene, and the HCV 3’UTR into the plasmid
18

A

B

Figure 8

Plasmid experimental design. A) pMCGL-T7 mutant plasmid containing the ampicillin
resistance gene, XbaI restriction site, T7 promoter sequence, and inserted gene sequence of interst
(5’UTR-gluc-4’UTR) B) Linearized plasmid
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following the T7 promoter site, but before the XbaI restrictioin site, this mutant plasmid
was named 5’UTR-gluc-3’UTR-plasmid (Figure 8A).

5’UTR-gluc-3’UTR was

transformed into E.coli BL21 competent cells and these cells were streaked onto LB agar
plates with 200 μg/mL of ampicillin and incubated overnight at 37°C. An individual
colony was chosen and cultured at 37°C at 250 rpm in 50 mL of LB media containing
ampicillin (200 μg/mL) for 12 to 16 hours until an OD600 between 2.0 and 3.0 was
reached.
The plasmid was extracted from the cells using the Omega Bio-tek E.Z.N.A
Endo-Free Plasmid Mini Kit II spin protocol before being digested with XbaI for 6 hours
at 37°C to linearize the plasmid. The linear plasmid then underwent transcription using a
T7 MEGAscript kit (Ambion-Applied Biosystems) to give us our final RNA transcript,
5’UTR-gluc-3’UTR. Our large RNA transcript 5’UTR-gluc-3’UTR was loaded onto a
1% Agarose gel and run at 150 V for approximately 1 hour in 1X TBE buffer before
being stained in ethidium bromide and visualized using UV trans-illumination at 254 nm.

2.5 PNA experiments
The PNAs were obtained from the Danith Ly laboratory at Carnegie Mellon
University. Two PNAs were designed, PNA-1 and PNA-S2, to be 15 nts in length
against specific sites of interest within the RNA genome (Figure 9A-B). They contained
lysine residues on alternating bases to ensure cell penetrating abilities (Figure 9C). PNA1 was designed against genotype 1a, whereas PNA-S2 was designed later on to cover a
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Figure 9

PNAs designed against S2 in the HCV 5’UTR (+). A) PNA-1 designed against genotype 2a B)
PNA-S2 designed against both genotype 1a and 2a C) PNA-1 showing cell penetrating ability
with alternating Lysine and MP residues.
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region that is identical in both genotypes 1a and 2a to have a good correlation with both
the in vivo data obtained using genotype 2a and the in vitro data obtained using genotype
1a. To analyze their interactions with the 5’UTR (+), PNA-1 or PNA-S2 were incubated
in different ratios to 5’UTR (+) for four hours at 37 °C. In a different set of experiments,
the ability of each of the two PNAs to displace miR-122 from its binding sites on the
5’UTR(+) was analyzed. The samples were run on a 20% native polyacrylamide gel at
4°C at 85 V for 7-8 hours, or on a 15% native polyacrylamide gel at 60 V at 37 °C for 1-2
hours. Fluorescently labeled with Cy3, PNA-S2 was also incubated with 5’UTR-gluc3’UTR in varying ratios and run on a 1% native agarose gel at room temperature at 150 V
for 1-2 hours before being visualized with a molecular dynamics Fluorimager 595 with
the excitation set at 570 nm.

22

Chapter 3: Characterization of the Hepatitis C Virus 5’ UTR interactions with the
microRNA miR-122
3.1

microRNA miR-122 interacts with a seed sequence within domain I of the

5’UTR of the HCV RNA genome.
miR-122 is a liver abundant microRNA that has been shown to interact with two seed
sequences within the positive sense strand of the 5’UTR of the HCV RNA genome. This
interaction has a role in both translation of the genome and RNA replication [26-28]. The
interactions have not been characterized, and the mechanisms by which they act on
translation and replication have not been fully elucidated. The role of this interaction
within the HCV life cycle is also unknown.
As mentioned previously, miRNAs begin in duplex form before the appropriate
strand is chosen in the RISC complex to become the mature miRNA. Because of this, it
is questionable what, if any, cell machinery outside of the RISC complex is needed for
the miR-122 duplex to mature and bind to the appropriate seed sequence within the HCV
5’UTR. Another question arises as to what occurs within the cell to allow miR-122 to
bind to the positive sense strand of the 5’UTR. RNA replication occurs from the minus
strand to make numerous plus strands to be used in the rest of the viral life cycle. While
this is occurring, a duplex between the plus and minus strand is formed. The question
then is, how does miR-122 invade this duplex, and does it even have to invade this
duplex? Or, once this duplex is opened by a different mechanism, is the role of miR-122
to bind to and “coat” the 5’UTR(+), preventing the reformation of the 5’UTR(+)3’UTR(-) duplex and allowing for the initiation of a new round of replication? We
performed a number of in vitro studies to examine the interactions involving both single23

Figure 10

TBE native gel of miR-122 (ss) interactions with the 5’UTR (+) with varying sample preparations
for each sample. Treatment types are: d - denaturation of the RNA by boiling for 5 minutes and
cooling to room temperature, s.a – slowly annealing the samples by boiling for 5 minutes and
cooling in the water over the period of 1 to 1 ½ hours, and s.c. – snap cooling the sample by
boiling for 3 minutes, placing immediately into a dry ice/ethanol mixture for 7 minutes, and
cooling to room temperature
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stranded and duplex miR-122 and 5’UTR (+) to address these questions. All of our
studies were performed in vitro, which does not always accurately mimic the conditions
within a cell.

3.1.1

Interactions of the Single-Stranded miR-122 with the HCV 5’UTR (+)

We began by examining the interactions between the chemically synthesized
single stranded miR-122 (miR-122 (ss)) and the chemically synthesized plus strand
5’UTR (5’UTR (+)). Various treatment methods were tested for the preparation of each
RNA sample, including snap-cooling, slow annealing, and denaturation (Figure 10). By
slowly annealing the samples, a second, higher band is present in lane 3, which we assign
to the formation of a non-physiological 5’UTR (+)-5’UTR (+) duplex, due to the slow
annealing conditions. The presence of this duplex will decrease the ability of miR-122
(ss) to bind, as its binding sites S1 and S2 on the 5’UTR (+) are not available within the
5’UTR (+)-5’UTR (+) duplex. Denaturing the RNA strands eliminates the 5’UTR (+)5’UTR (+) duplex band (figure 10 lane 5), but this also results in the loss of the
secondary structure stem loop of the 5’UTR (+), which must be snap-cooled to form the
stem-loop structure motif. miR-122 (ss) migrated similarly regardless of the method of
RNA treatment, so it was determined that both RNA samples would be snap-cooled
separately then incubated together at room temperature for 10-15 min to allow miR-122
(ss) to bind to the seed sequence targets located within the 5’UTR (+).
As seen in figure 11, under these conditions, a single band was present for the
single stranded 23 nt miR-122 (lane 1) or the 46 nt 5’UTR (+) (lane 2), whereas, a new,
shifted band appears upon the addition of miR-122 (ss) to 5’UTR (+) in a 1:1 ratio (lane
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Figure 11

TBE native gel of miR-122 (ss) interactions with the 5’UTR (+) with increasing ratios of
5’UTR (+) : miR-122. The lower band corresponds to miR-122 (ss), the middle band
corresponds to 5’UTR (+), and the upper band corresponds to the 5”UTR (+)-miR-122 complex.
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3), corresponding to the formation of their complex. This shift of the free 5’UTR (+)
band in the presence of miR-122 is small, likely corresponding to the complex formed by
the binding of a single miR-122 (ss) to 5’UTR (+). Increasing ratios of miR-122: 5’UTR
(+) were analyzed to determine if, present in excess, miR-122 could bind to both target
binding sites S1 and S2 simultaneously. As seen in lanes 4 and 5 in vitro, only one miR122 (ss) can bind 5’UTR (+), as an increase of intensity of the free miR-122 (ss) band
was observed, but no new higher shifted band that would correspond to the size of the
complex formed by 5’UTR (+) and two miR-122 (ss). Note that from these experiments
alone, we cannot distinguish if the single miR-122 (ss) binds preferentially to site S1 or
S2 or if the band we observe corresponds to a mixture with either site S1 or S2 being
occupied by miR-122.
1

H NMR spectroscopy experiments were also performed to examine the structure

of the 5’UTR(+) alone and in the presence of miR-122, as well as miR-122 alone (Figure
12). While performing 1H NMR spectroscopy on RNA samples, the range of interest is
between 10.00-15.00 parts per million (ppm), corresponding to imino proton resonances.
These imino protons will only be seen in NMR when they are involved in base pairs
through hydrogen bonding, as in the duplex form of RNA, as in unbound form they will
be in fast exchange with water protons, resonating at 4.76 ppm. The bottom spectrum in
figure 12 corresponds to the free miR-122, and as expected, no imino proton resonances
are visible, as no secondary structure is predicted to exist within miR-122 RNA.
The imino proton resonances observed for free 5’UTR (+) (figure 12, middle
spectrum) are consistent with the stem loop structure predicted for this RNA sequence
(Figure 6A), with mostly G-C base pair resonances (11.50-13.00 ppm), and one A-U

27

resonance (13.00-15.00 ppm), assigned to the bond between U-10 and A-14. The G-C
resonances are heavily overlapped due to the fact that the local environment of the G
imino protons is very similar in this stem sequence (figure 6A). The addition of miR-122
(ss) to 5’UTR (+) in a 1:1 ratio results in the apparition of a new set of resonances
corresponding to the Watson-Crick base pairs formed upon the binding of miR-122 (ss)
to its target site within 5’UTR (+). It is important to note that the original resonances for
5’UTR (+) remain, indicating that the GC-rich stem loop is maintained, even upon miR122 (ss) binding. Surprisingly, resonances were seen in the wobble GU base-pair region
of the NMR spectrum. Our original structural model for the binding of miR-122 (ss) to
5’UTR (+) did not predict G-U base pairs predicted (Figure 6B), but RNAStructure
predicted a G-U base pair through a supplementary binding site for S2 (Figure 6C green
oval).
If miR-122 (ss) is binding at the supplemental site through a G-U wobble base
pair, it may be assumed that, in vitro, one miR-122 (ss) binds at S2 and its supplemental
sites, and that a second miR-122 (ss) cannot bind at S1. This hypothesis is supported by
the native gel electrophoresis results. Overall, the in vitro data involving single-stranded
RNA strands shows that only one miR-122 (ss) binds to one seed sequence within
5’UTR(+), presumably S2.
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Figure 12

NMR spectroscopy spectra of miR-122 (ss) (lower blue spectrum), 5’UTR (+) (middle red
spectrum), and the 5’UTR (+)-miR-122 (ss) complex (upper dark blue spectrum). G-C base pair
resonances are seen between 11.50 and 13.00 ppm, A-U resonance are seen between 13.00 and
15.00, and G-U resonances are seen between 10.00 and 12.00 ppm
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3.1.2

miR-122 duplex interactions with the HCV 5’UTR (+)

Our next question was whether or not duplex miR-122 (miR-122 (dx)) will be
able to separate into what would be the mature miR-122 and its complementary sequence
and allow the mature miR-122 (ss) to bind to 5’UTR (+) in vitro. The 5’UTR (+) was
prepared by snap cooling, as performed for our previous experiments, whereas miR-122
(dx) was used without any further preparation. As seen in figure 13A, even at low ratios
of 5’UTR (+):miR-122 (dx), the duplex does not separate and bind 5’UTR (+). These
results were expected, as within the cell the RISC complex is required to separate the
microRNA duplex and allow the mature miR-122 to be loaded onto the 5’UTR seed
sequence(s). It can be noted that both 5’UTR (+) and miR-122 (dx) are 46 nts in length,
but do not run at the same position on the gel. This is most likely a result of the stem
loop formed in 5’UTR (+) (figure 6A) retarding the RNA while it runs through the gel,
and miR-122 (dx) taking a linear form that is able to run more freely through the gel.
Conversely, we wondered if miR-122 (ss) could invade the 5’UTR duplex formed
between the plus and minus (3’UTR (-)) strands during RNA replication (5’-3’UTR
(dx)). 5’UTR (+) was slowly annealed over an hour to 3’UTR (-) before being incubated
with miR-122 (ss). Increasing concentrations of miR-122 (ss) were incubated with a
constant concentration of 5’-3’UTR (dx) to allow miR-122 to find and bind to the seed
sequence within the 5’UTR (+). Figure 13B shows that this did not occur, and once
again, the conclusion can be drawn that some part of the cell machinery is necessary for
the unwinding of the 5’UTR duplex.
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A

B

Figure 13

TBE native gel of duplex/complex interactions. A) Increasing concentrations of the miR-122
(dx) were incubated at room temperature with a constant concentration of 5’UTR (+) B)
increasing concentrations of the 5’UTR (+)-3’UTR (-) concentration were incubated at room
temperature with a constant concentration of miR-122 (ss)
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3.2 Conclusion: Single-stranded miR-122 interacts in vitro with the HCV 5’UTR
plus strand
We have shown that miR-122 interacts with the HCV 5’UTR sequence
complementary to the miR-122 seed sequence in a 1:1 ratio. We are unable to determine
definitively if this interaction is occurring with the S1 or S2 binding sites, but a structural
map of the interactions has previously shown the direct interaction is occurring at S2[48].
Their suggested interactions are supported by our 1H NMR spectroscopy studies, which
show the existence of a G-U wobble base pair.
EMSA studies have shown that miR-122 (ss) binds to the 5’UTR (+), but cannot
invade the duplex formed between the 5’UTR (+) and 5’UTR (-). This is most likely
because our experiments were performed in vitro, without the Argonaut protein and RISC
complex, which are required for the loading of microRNAs onto their mRNA targets.
The Ago protein and RISC complex are also needed to separate the two strands in the
miR-122 (dx) so that the correct, mature strand, can bind to the 5’UTR (+). Through
EMSA and NMR spectroscopy, initial characterizations of the interactions between miR122 and the HCV 5’UTR have been accomplished.
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Chapter 4: Peptide Nucleic Acids as therapeutic agents against HCV
4.1 PNA can inhibit the interactions between miR-122 and its binding site S2
within the 5’UTR (+).
The use of peptide nucleic acids (PNAs) in therapeutic development is an
evolving field in the sciences. Because of this, we designed and investigated the activity
of a PNA molecule which aims to disrupt the interactions between miR-122 and its
binding site S2 within the HCV 5’UTR (+). PNAs are ideal for this sort of “job” due to
their ability to bind specifically and with high affinity to their complementary DNA or
RNA, their high stability, and their inability to be degraded by proteases and nucleases.
Most importantly for their use as therapeutic agents is the fact that PNAs can easily
invade duplex DNA or RNA, disrupting normal interactions and functions of the nucleic
acids.
In this study, we investigated two PNAs designed against the 5’UTR (+) sequence
S2 (PNA-1 and PNA-S2) (Figure 9) with the expectation that they will disrupt the
interaction between the 5’UTR (+) and miR-122 (ss), which could possibly inhibit
translation and/or RNA replication of the virus. While the mechanism of interaction
between miR-122 and the 5’UTR is still unknown, it has been shown that the interaction
is essential for translation and RNA replication[33, 34]. These PNAs were designed to be
15-nts long and synthesized in the laboratory of Dr. Danith Ly of Carnegie Mellon
University. While PNA experiments had previously been performed in our laboratory,
giving a general starting point for the sample preparation, the experimental conditions
must be tested for each specific PNA.
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Figure 14

The entire HCV 5’UTR RNA sequence of genotypes 1-6 with select subtypes. Sequences are
aligned to the H77 position and numbering is according to the H77 reference sequence. A dot
indicates that the nucleotide is identical to H77, a dash indicates a gap. The nucleotides formint
the SL1 structure is indicated, and the miR-122 binding sites are shaded[18].
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While the miR-122 seed sequences within the HCV 5’UTR are 100% conserved,
the remaining nucleotides within the 5’UTR are not conserved (Figure 14). Because of
this, the original PNA-1 designed was only successful against genotype 2a, but PNA-S2
was designed to be used with the genotype 2a, as well as with genotype 1a.

4.1.1 PNA-1
The original studies were performed with PNA-1 that was designed against S2
within the 5’UTR (+) (genotype 2a). First, the optimum incubation time and temperature
for the PNA-5’UTR (+) were determined. Following the incubation of PNA-1 with
5’UTR (+) in a 1:1 ratio for 1, 2, and 4 hours at 37°C and 21°C, the samples were run on
a 20% native gel (Figure 15). As seen in figure 15A (top), it was determined that minimal
binding occurred when the samples were incubated at 21°C.

A complex between the

5’UTR (+) and PNA-1 was clearly observed following incubation at 37°C for 4 hours
(figure 15B). These conditions were used for the rest of the experiments involving PNA1.
Next, we performed experiments to determine the optimal ratio of 5’UTR (+):
PNA-1. At a ratio of 1:1, the band corresponding to the 5’UTR (+)-PNA-1 complex is
visible, but the free 5’UTR (+) band was still present. The optimal ratio was found to be
1:2 in which the band corresponding to the 5’UTR (+)-PNA-1 complex is present,
indicating that all the 5’UTR (+) was bound by PNA-1. At a ratio of 1:4, a new, higher
band is seen, which may be caused by non-specific binding, creating a higher molecular
weight species, which is undesired.

35

A – 21°C

B - 37°C

Figure 15

TB native gel containing 10 mM cacodylic acid, pH 6.5, 10 mM NaCl, and 25 mM KCl. A ratio
of 5’UTR (+) : miR-122 (ss) : PNA-1 of 1:1:1 was used in both gels with different incubation
lengths. The samples were incubated for the described length of time A) at room temperature (21
°C) and B) 37°C
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Figure 16

TB native gel containing 10 mM cacodylic acid, pH 6.5, 10 mM NaCl, and 25 mM KCl showing
that PNA-1 preferentially binds to 5’UTR (+) over miR-122 (ss). The lowest band is miR-122
(ss) which is seen to appear with the addition of PNA-1 (lane 5) without the appearance of the
5’UTR (+)-miR-122 (ss) complex (lane 3).

37

Next, we investigated if PNA-1 is able to disrupt the interactions between miR122 (ss) and the 5’UTR (+). The miR-122 and 5’UTR (+) were incubated first to ensure
they form a complex, and then upon the addition of PNA-1 in a 1:2 ratio, the samples
were incubated at 37°C for 4 hours. Lane 5 in figure 16 shows that, in the presence of
PNA-1, there is a band corresponding to the free miR-122 (ss) that is displaced by PNA1.
4.1.2 PNA-S2
Our collaborator, Dr. Stanley Lemon at the University of North Carolina Chapel
Hill Inflammatory Diseases Institute, performed in vivo experiments with PNA-1, which
is designed against genotype 2a. Genotype 2a differs by one nucleotide within the PNA1 binding site from the genotype 1a, the most common HCV genotype. Because the
genotypes are 100% conserved for the miR-122 seed sequences and highly conserved for
the remainder of domain I of the 5’UTR, there are not too many bases that vary between
genotypes (figure14). This allowed us to design a new PNA that would be successful
against both genotype 1a and 2a, PNA-S2 (Figure 9B).
This PNA-S2 does not have the cell penetrating ability of PNA-1 since we are
using it only in vitro experiments. This was done to eliminate the tails seen on the gels
containing PNA-1, which are caused by the highly positive charge of the PNA-1,
conferred by the lysine residues present in PNA-1, which gave it cell penetrating
properties.

PNA-S2 was also tagged at the N-terminus with the fluorescent molecule

Cy-3 to be able to monitor its interactions with a 1.2 kb chimeric RNA which has the
HCV 5’UTR and 3’UTR flanking the luciferase gene. The fluorophore Cy 3 has the
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Figure 17

TB native gel containing 10 mM cacodylic acid, pH 6.5, 10 mM NaCl, and 25 mM KCl.
1.0 μM 5’UTR (+) was held constant with increasing concentrations of PNA-S2.
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B) Salt has been added to the gel

A) No salt is in the gel

Figure 18

TB native gel containing A) no salts in the gel and B)10 mM cacodylic acid, pH 6.5, 10 mM
NaCl, and 25 mM KCl in the gel. Both sets of samples were made in a salt buffer containing 10
mM cacodylic acid, pH 6.5, 10 mM NaCl, and 150 mM KCl. The addition of salt to the gel
eliminates the trailing effect seen in our gels. This salt gel was used for the remainder of our
experiments.
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excitation maxium at 550 nm and the emission at 570 nm, putting it within the visible
spectrum, and giving it a characteristically red/pink color.
Concentration dependent studies were carried out for PNA-S2, and it was
determined that a ratio of 5’UTR: PNA-S2 of 1:2 was sufficient (Figure 17), and an
incubation time of 30 min at 37°C would be used. 15% native polyacrylamide gels were
run at 37°C at 60 V for approximately 2 hours before being stained by SybrGold and
visualized using the AlphaInnotech AlphaImager.
The original experiments were performed in 10 mM cacodylic acid buffer, pH
6.5, which led to a trailing effect for the lanes of the gel, as well as nonspecific binding of
the PNA (Figure 18A). To eliminate these problems, a salt buffer was used with 10 mM
cacodylic acid, pH 6.5, 10 mM NaCl, and 150 mM KCl. These salts were also added to
the gel to eliminate the trailing effect (Figure 18B).
The concentration of 5’UTR (+) and miR-122 in the samples were 2.5 μM, with
the concentration of PNA-S2 being 7.5 μM. The binding experiments showed that PNAS2 is able to invade the complex formed between miR-122 (ss) and the HCV 5’UTR (+),
resulting in the release of the miR-122, which appears as a new, lower band on the gel
(Figure 19, lane 5). If the miR-122 was binding to the 5’UTR (+) the 5’ UTR (+)-miR122 complex band would be seen instead.
Our results showed that PNA-S2 has the ability to bind to the HCV 5’UTR (+),
which is only 46 nts in length. It was important to show that PNA-S2 could bind to the
same site, but in the context of the entire 341 nt 5’UTR. To do this, PNA-S2 was
incubated with 1.2 kb 5’UTR-gluc-3’UTR construct for 2 hours at 37°C and run on a 1%
agarose gel. Due to the large size disparity between the RNA (1,213 nts) and PNA (15
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Figure 19

TB native gel containing 10 mM cacodylic acid, pH 6.5, 10 mM NaCl, and 25 mM KCl showing
that PNA-S2 invades the 5’UTR (+) - miR-122 (ss) complex. The lowest band is miR-122 (ss)
which is seen to appear with the addition of PNA-S2 (lane 5) without the appearance of the
5’UTR (+)-miR-122 (ss) complex (lane 3).
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A

B

Figure 20

1% Agarose gel showing that PNA-S2 binds to 5’UTR-gluc-3’UTR. A. Cy3 excitation is seen on
the Fluoroimager for the lanes containing PNA-S2 only. B. Ethidium bromide staining reveals
the band corresponding to free RNA in lane 2 (Current gels were provided by Becky Barnard).
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bases), gel shift assays would not be successful in showing that binding occurred because
the shift in the band would not be seen. Because PNA-S2 is fluorescently labeled with
Cy3, a Molecular Dynamics Fluoroimager 595 was used to excite the samples in a gel at
570 nm (the excitation of Cy3), allowing us to visualize the binding of the PNA to the
RNA. Figure 20 A shows that PNA-S2 can bind to longer and more complex strands of
RNA. The gel was subsequently stained by ethidium bromide to show all of the RNA
bands, including the free RNA (figure 20B, lane 2), showing that PNA-S2 successfylly
binds to the full-length 5’UTR.

4.2 Conclusion: PNAs as a successful inhibitor of the interactions between
miR-122 and HCV 5’UTR
PNAs designed against HCV genotypes 1a and 2a are successful in inhibiting the
interactions between miR-122 (ss) and its complementary binding site within the 5’UTR
(+). This is important because of its potential to be used as a therapeutic agent to help
treat the virus.

The interactions between the miR-122 seed sequence and its

complementary sequence within the HCV 5’UTR are essential for RNA replication and
translation, and are 100% conserved among all the HCV genotypes, making them an
ideal therapeutic target for PNAs.
Two PNAs were designed for our study, both of which were able to interact
preferentially with their target sequence within the 5’UTR (+), displacing miR-122 (ss).
PNA-S2 was designed to target genotype 1a and 2a and was fluorescently tagged with a
Cy3. This made it easy to study its interactions with the full length HCV 5’UTR through
agarose gel electrophoresis. PNA-S2 was successful in binding to the HCV 5’UTR-gluc44

3’UTR sequence in agarose gels.

Due to the large disparity in size between HCV

5’UTR-gluc-3’UTR (~900 bases) and miR-122 (23 nt), they were not able to be run on
the same gel to prove that the binding of PNA-S2 is preferential over miR-122 (ss) in the
full 5’UTR sequence, but the short 5’UTR (+) was successful in this outcome.
Overall, PNA-1 and PNA-S2 are promising for the future of therapeutic agents for
chronic HCV viral infections. Preliminary in vivo experiments performed by Dr.
Mihailescu in the laboratory of Dr. Stanley Lemon at UNC show that PNA-1 is able to
inhibit the HCV replication in Huh7 hepatic cell lines.
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Chapter 5: Conclusions
Chronic hepatitis C virus (HCV) infects more than 130 million people worldwide,
and there is still no complete therapeutic option to effectively treat all of the different
genotypes and subtypes. Because of the genome’s highly mutational nature, it is difficult
to characterize the virus, and any sequence within the HCV genome with high or
complete conservation must be examined for the potential of developing new therapeutic
options.
In this study, two 100% conserved sequences, complementary to the miR-122 see
sequence, within the HCV 5’UTR were investigated in vitro as potential therapeutic
targets. These two sequences are involved in essential interactions with the microRNA
miR-122, and our EMSA gels and 1H NMR spectroscopy experiments showed that they
interact in a 1: 1 ratio, most likely as a result of a single miR-122 binding to S2 within the
5’UTR. We were also able to show that, in vitro, it is necessary for the miR-122 and the
5’UTR to be single-stranded to allow the interactions to occur. From this, we can infer
that the cellular machinery, most likely parts of the RISC complex, is necessary for the
interactions to occur in their natural double stranded forms.
Once we determined that the 5’UTR and miR-122 interact in vitro, PNAs were
designed to interrupt the interactions. Two PNAs were designed to do this: one that was
specific to genotype 2a and a second that worked against genotypes 1a and 2a. Both of
these PNAs were shown to bind preferentially over miR-122 to the seed sequences within
the 5’UTR. The second PNA was fluorescently labeled with Cy3, and we were able to
use it to show that the PNA could bind to a longer RNA strand with secondary structure
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elements. These are promising results for the potential future of PNA as a therapeutic
strategy against HCV.
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Chapter 6: Future Research
As mentioned previously, these studies were all carried out in vitro without the
RISC complex and more specifically the Argonaute protein Ago2. It has been suggested
that Ago2 acts coordinately with miR-122 to slow the decay of the viral genome in
infected cells[49]. To further investigate the interactions between the HCV 5’UTR and
miR-122, cell lysates containing Ago2 need to be used. The RNA strands would be
extracted from the lysates and biophysical methods would be used to study if the
interactions are different in the presence of Ago2. Biotinylating the HCV 5’UTR would
allow easier extraction of the cell lysates, while leaving the 5’UTR and bound miR-122
to be studied.
PNAs have the potential to work as therapeutic agents for different conserved
sites within the HCV RNA genome. PNA against domain IIId within the 5’UTR IRES
genotype 1a has been designed and made by the Ly laboratory. This PNA is designed to
inhibit the IIId interaction with a stem-loop found within the NS5B region of the RNA
that is essential for translation. Similar PNA experiments would be carried out and
performed to check the efficiency of new and different PNAs as potential chronic
hepatitis C antiviral therapies.
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